Nyxoah (NASDAQ:NYXH) Upgraded at Wall Street Zen

Nyxoah (NASDAQ:NYXH) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday, Wall Street Zen reports.

Several other equities research analysts also recently commented on NYXH. Weiss Ratings reissued a “sell (e+)” rating on shares of Nyxoah in a research report on Wednesday, August 19th. Cantor Fitzgerald decreased their price target on Nyxoah to $3.00 and set an “overweight” rating on the stock in a research note on Tuesday, October 27th. Oppenheimer set a $4.00 price target on Nyxoah in a research note on Thursday, August 6th. Raymond James Financial set a $3.00 price target on Nyxoah in a research note on Tuesday, October 27th. Finally, Robert W. Baird set a $2.31 price target on Nyxoah in a report on Thursday, August 6th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Nyxoah has an average rating of “Hold” and an average target price of $3.55.

Nyxoah Price Performance

Shares of NASDAQ NYXH opened at $0.85 on Friday. Nyxoah has a 12 month low of $0.80 and a 12 month high of $5.92. The stock has a market capitalization of $32.78 million, a price-to-earnings ratio of -0.43 and a beta of 1.80. The firm’s 50 day simple moving average is $1.27 and its 200-day simple moving average is $2.42. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.38 and a quick ratio of 2.31.

Nyxoah (NASDAQ:NYXH) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.04. Nyxoah had a negative return on equity of 178.90% and a negative net margin of 443.16%. The business had revenue of $10.39 million for the quarter, compared to the consensus estimate of $11.00 million. Analysts expect that Nyxoah will post -1.46 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. AIGH Capital Management LLC grew its stake in shares of Nyxoah by 0.7% during the 3rd quarter. AIGH Capital Management LLC now owns 14,632,880 shares of the company’s stock worth $20,193,000 after purchasing an additional 98,000 shares during the period. Integrated Wealth Concepts LLC purchased a new position in Nyxoah during the 2nd quarter valued at about $169,000. IFP Advisors Inc lifted its holdings in Nyxoah by 35.6% in the 2nd quarter. IFP Advisors Inc now owns 118,426 shares of the company’s stock worth $200,000 after purchasing an additional 31,061 shares during the last quarter. Finally, Readystate Asset Management LP acquired a new stake in shares of Nyxoah during the 2nd quarter worth approximately $351,000.

Nyxoah Company Profile

Nyxoah SA is a medical technology company focused on developing and commercializing solutions for obstructive sleep apnea (OSA), a common sleep-related breathing disorder. The company is headquartered in Mont-Saint-Guibert, Belgium, and its shares trade on the Nasdaq under the symbol NYXH.

Nyxoah’s principal product is the Genio system, an implantable, rechargeable device designed to treat OSA through hypoglossal nerve stimulation. The system is intended to help maintain an open airway during sleep by stimulating the nerves that control the tongue and related upper-airway muscles.